| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 2,001 | 1,508 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -382,216 | -378,159 |
| Cash and cash equivalents at beginning of period | 431,421 | - |
| Cash and cash equivalents at end of period | 49,205 | - |
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)